GlaxoSmithKline,
Shire, Emory University Announce Agreement on Patent Rights
GlaxoSmithKline
(NYSE: GSK), Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY,
TSE: SHQ) and Emory University announce they have signed the final agreement
in settlement of global disputes over certain patent rights relating
to lamivudine and emtricitabine. The agreement includes settlement of
related U.S. litigation.
Under the terms of the settlement,
Emory University receives a license under Shire's patents related to
emtricitabine and Shire and GSK receive licenses under Emory University's
patents related to lamivudine.
Triangle Pharmaceuticals
is developing Coviracil® (emtricitabine) for the treatment of HIV
infections under license from Emory University.
GlaxoSmithKline developed
and markets Epivir® (lamivudine) for the treatment of HIV under
license from Shire. Shire and GSK jointly market 3TC® (lamivudine)
in Canada. GlaxoSmithKline – one of the world's leading research-based
pharmaceutical and healthcare companies – is committed to improving
the quality of human life by enabling people to do more, feel better
and live longer.
Shire Pharmaceuticals Group
plc (Shire) is a rapidly growing international specialty pharmaceutical
company with a strategic focus on three therapeutic areas – central
nervous system disorders (CNS), oncology and anti-infectives. Shire
also has two platform technologies: advanced drug delivery and biologics.
Shire's core strategy is based on research and development combined
with in licensing and a focus on eight key pharmaceutical markets.
Emory University is a leading
research university with one of the fastest-growing research enterprises
in the nation. Emory is known for its highly recognized professional
schools of medicine, public health, nursing, business, law, and theology,
as well as for its advanced research facilities and an unprecedented
expansion of research support in the health sciences.
MEDIA INQUIRIES:
GLAXOSMITHKLINE
UK Media
Martin Sutton, 020 8047 5502
Alan Chandler, 020 8047 5502
US Media
Nancy Pekarek, 215 751 7709
Patricia Seif, 215 751 7709
Mary Anne Rhyne, 919 483 2839
SHIRE
Global (outside U.S. and Canada)
Investor Relations
Clea Rosenfeld, 44 1256 894 160
Media
Jessica Mann, 44 1256 894 280
U.S. and Canada
Investor Relations
Gordon Ngan, 1 450 978 7938
Media
Michele Roy, 1 450 978 7876
EMORY UNIVERSITY
Media
Holly Korschun 404-727-3990
Ron Sauder 404-727-3366
|